The technology integrates the latest advancements in robotics, software, data science and endoscopy (the use of small cameras and tools to enter the body through its natural openings). Bon Secours is among the first hospitals in the United States to utilize the platform, which was recently cleared by the U.S. Food and Drug Administration (FDA).
"Lung cancer is the leading cause of cancer deaths worldwide, in part because it has no symptoms in its early stages. Because the Monarch™ Platform provides improved reach, vision and control for bronchoscopic procedures, it holds potential to help us to make a diagnosis earlier,” Dr. Ezzat El-Bayoumi, a Bon Secours pulmonologist, said. “We are excited about the promise of this technology to offer a more hopeful future for our patients with lung cancer.”
More than 90 percent of people diagnosed with lung cancer do not survive the disease, in part because it is often found at an advanced stage. There are a variety of diagnostic options currently available for lung cancer, but all have limitations in accuracy, safety or invasiveness. These limitations can lead to false positives, false negatives or side effects such as pneumothorax (collapsed lung) and hemorrhage, which may increase health care costs and extend hospital stays.
The Monarch™ Platform utilizes a familiar controller-like interface that physicians use to navigate the flexible robotic endoscope to the periphery of the lung with improved reach, vision and control. Combining traditional endoscopic views into the lung with computer-assisted navigation based on 3D models of the patient’s own lung anatomy, the Monarch™ Platform provides physicians with continuous bronchoscope vision throughout the entire procedure.
For more information about Bon Secours services, locations, and happenings, visit bonsecours.com.